Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 May 2021 | Story Leonie Bolleurs | Photo Supplied
Dr Hlami Ngwenya believes that the UFS has a key role to play in Africa.

Dr Hlami Ngwenya, Lecturer in the Department of Sustainable Food Systems and Development at the University of the Free State (UFS), describes herself as a social scientist and global citizen – having worked in more than 50 countries, with more than 30 years of experience. 

She is equipping students to make a difference in their communities, whether it is here in South Africa, or in other countries in Africa where they reside and beyond. Dr Ngwenya joined the UFS in 2015, teaching the Advanced Diploma on Extension for Sustainability and the Master’s Programme on Sustainable Agriculture and Extension: Theory and Practice. 

Investing in farmers’ human capital globally

She has made major contributions to the field with her research work. In 2020, she contributed a chapter on ‘Food and Agriculture’ in the United Nations Development Programme (UNDP) report on COVID-19 Rapid Emergency Needs Assessment for the most vulnerable groups. In addition, she was part of a global study titled, Investing in farmers: Agriculture Human Capital Investment (AHCI) strategies, conducted in partnership with the International Food Policy Research Institute (IFPRI) and the Food and Agriculture Organisation (FAO Investment Centre).  

The latter study was conducted in nine countries in Africa, Asia, and Latin America. The aim was to improve the understanding of AHCI. The study also provides lessons learned from successful AHCI models around the world, with recommendations and guidelines for future investment that enhances the human capital of agricultural producers.

This year, she is working on a research paper titled, Demystifying facilitation of systemic change and the role of agriculture extension towards sustainable development and resilient food systems: analytical, conceptual and theoretical underpinnings.

Her input is also valued by paramount bodies in the industry, such as the Global Forum for Rural Advisory Services (GFRAS). Dr Ngwenya is a member of the GFRAS Consortium for Education and Training, and she is playing a significant role in terms of agricultural extension and advisory services at a global level. 

Global tool with local relevance 

She is also one of the faces behind the globally developed New Extensionist Learning Kit. Commonly known as NELK, this GFRAS product was created as a tool to augment and equip agricultural extension personnel with the functional skills relevant to managing the complexities of agricultural innovation and food systems. 

The UFS Department of Sustainable Food Systems and Development is one of the leading institutions globally that has adopted and adapted NELK as part of its curriculum. The South African Society for Agricultural Extension (SASAE) has also adopted the kit to contribute towards the continuous professional development of extension personnel. 

On the African continent, Dr Ngwenya has been a resource person for the African Forum for Agricultural Advisory Services (AFAAS) and supported the development of agricultural extension and advisory services fora at regional and national levels. 

Here on home soil, she continues to be involved with SASAE, supporting them in facilitating their strategic planning processes and professionalisation activities.

Spreading her wings beyond extension 

Beyond her active involvement in the agricultural extension field, Dr Ngwenya is a role player in other areas of agriculture globally. This includes agricultural policy, agricultural research, as well as agricultural education.  She brings all this knowledge and skills to benefit her students and the university. 

In her lifetime, she has had the opportunity to moderate more than 300 multi-stakeholder engagements, including strategic planning sessions, organisational development, team building, training, and conferences. These include high-level policy dialogues at United Nations level, the African Union Commission, and other continental and regional level organisations. 

Humbleness is empowering 

Although she had the chance to travel the world and engage at the highest level, she believes that it is important to be humble. She makes an effort to respect and cherish people for who they are, their cultures, and different systems. 

“One of the most valuable lessons I have learnt through engaging in many African countries, is that there is not necessarily co-relation between a country’s strong economy and human capital.” Despite the socio-political challenges that many countries go through (including ours), there are many genuine, hard-working, and intelligent people out there,” she says. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept